• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫调节框架及微小RNA在非小细胞肺癌发病机制中的作用——一项系统综述

Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC - A systematic review.

作者信息

Samarth Nikhil, Gulhane Pooja, Singh Shailza

机构信息

National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune, India.

出版信息

Front Oncol. 2022 Dec 21;12:1089320. doi: 10.3389/fonc.2022.1089320. eCollection 2022.

DOI:10.3389/fonc.2022.1089320
PMID:36620544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9811680/
Abstract

With a 5-year survival rate of only 15%, non-small cell lung cancer (NSCLC), the most common kind of lung carcinoma and the cause of millions of deaths annually, has drawn attention. Numerous variables, such as disrupted signaling caused by somatic mutations in the EGFR-mediated RAS/RAF/MAPK, PI3K/AKT, JAK/STAT signaling cascade, supports tumour survival in one way or another. Here, the tumour microenvironment significantly contributes to the development of cancer by thwarting the immune response. MicroRNAs (miRNAs) are critical regulators of gene expression that can function as oncogenes or oncosuppressors. They have a major influence on the occurrence and prognosis of NSCLC. Though, a myriad number of therapies are available and many are being clinically tested, still the drug resistance, its adverse effect and toxicity leading towards fatality cannot be ruled out. In this review, we tried to ascertain the missing links in between perturbed EGFR signaling, miRNAs favouring tumorigenesis and the autophagy mechanism. While connecting all the aforementioned points multiple associations were set, which can be targeted in order to combat NSCLC. Here, we tried illuminating designing synthetically engineered circuits with the toggle switches that might lay a prototype for better therapeutic paradigm.

摘要

非小细胞肺癌(NSCLC)是最常见的肺癌类型,也是每年数百万人死亡的原因,其5年生存率仅为15%,这引起了人们的关注。许多变量,如表皮生长因子受体(EGFR)介导的RAS/RAF/丝裂原活化蛋白激酶(MAPK)、磷脂酰肌醇-3激酶(PI3K)/蛋白激酶B(AKT)、Janus激酶(JAK)/信号转导子和转录激活子(STAT)信号级联中的体细胞突变导致的信号传导中断,都以某种方式支持肿瘤的存活。在这里,肿瘤微环境通过阻碍免疫反应显著促进癌症的发展。微小RNA(miRNA)是基因表达的关键调节因子,可作为癌基因或抑癌基因发挥作用。它们对NSCLC的发生和预后有重大影响。尽管有无数种治疗方法可供使用,而且许多正在进行临床试验,但耐药性、其副作用和导致死亡的毒性仍不能排除。在这篇综述中,我们试图确定EGFR信号传导紊乱、促进肿瘤发生的miRNA和自噬机制之间缺失的环节。在连接所有上述要点时建立了多个关联,这些关联可以作为对抗NSCLC的靶点。在这里,我们试图阐明用拨动开关设计合成工程电路,这可能为更好的治疗模式奠定一个原型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/a83d9697d1c6/fonc-12-1089320-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/8ed779c1f184/fonc-12-1089320-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/f2dbfb175145/fonc-12-1089320-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/b42bfd4e4770/fonc-12-1089320-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/a39e11a27041/fonc-12-1089320-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/40b77c49b100/fonc-12-1089320-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/6118e81ca376/fonc-12-1089320-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/a83d9697d1c6/fonc-12-1089320-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/8ed779c1f184/fonc-12-1089320-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/f2dbfb175145/fonc-12-1089320-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/b42bfd4e4770/fonc-12-1089320-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/a39e11a27041/fonc-12-1089320-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/40b77c49b100/fonc-12-1089320-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/6118e81ca376/fonc-12-1089320-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e8/9811680/a83d9697d1c6/fonc-12-1089320-g007.jpg

相似文献

1
Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC - A systematic review.免疫调节框架及微小RNA在非小细胞肺癌发病机制中的作用——一项系统综述
Front Oncol. 2022 Dec 21;12:1089320. doi: 10.3389/fonc.2022.1089320. eCollection 2022.
2
Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.非小细胞肺癌的细胞行为受 EGFR 和 microRNAs 调控。
Int J Mol Sci. 2021 Nov 19;22(22):12496. doi: 10.3390/ijms222212496.
3
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变(EGFR)检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂(TKI)药物疗效的预测:一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
4
MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.微小 RNA 作为 EGFR 突变型非小细胞肺癌靶向治疗耐药的机制:当前意义与未来方向。
Drug Resist Updat. 2019 Jan;42:1-11. doi: 10.1016/j.drup.2018.11.002. Epub 2018 Nov 28.
5
Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.在具有表皮生长因子受体(EGFR)激活突变的晚期非小细胞肺癌(NSCLC)患者中,鉴定对EGFR酪氨酸激酶抑制剂(EGFR-TKIs)原发性耐药的血浆微小RNA谱。
J Hematol Oncol. 2015 Nov 12;8:127. doi: 10.1186/s13045-015-0210-9.
6
Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.胃癌中致癌物作用的分子机制及靶向治疗一瞥
Cell Oncol (Dordr). 2022 Dec;45(6):1073-1117. doi: 10.1007/s13402-022-00715-3. Epub 2022 Sep 23.
7
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.中国非小细胞肺癌患者中NSCLC肿瘤克隆的竞争性进化及第一代EGFR-TKIs的耐药机制
Heliyon. 2018 Dec 19;4(12):e01031. doi: 10.1016/j.heliyon.2018.e01031. eCollection 2018 Dec.
8
miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.miR-19b 通过靶向非小细胞肺癌中的 PP2A 和 BIM 增强 EGFR 信号通路促进增殖和抗凋亡。
Mol Cancer. 2018 Feb 19;17(1):44. doi: 10.1186/s12943-018-0781-5.
9
Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.在非小细胞肺癌球体中通过垂直抑制表皮生长因子受体(EGFR)信号传导显示出显著的协同作用,表明SOS1是EGFR突变癌症的一个治疗靶点。
Elife. 2020 Sep 8;9:e58204. doi: 10.7554/eLife.58204.
10
Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.表皮生长因子受体酪氨酸激酶抑制剂及其下游信号通路在非小细胞肺癌中的分子靶向治疗。
J Chin Med Assoc. 2022 Apr 1;85(4):409-413. doi: 10.1097/JCMA.0000000000000703.

引用本文的文献

1
METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.METTL16依赖的miR-146b-5p m6A修饰重塑通过激活PI3K/AKT信号通路使非小细胞肺癌对奥希替尼敏感。
BMC Cancer. 2025 Apr 8;25(1):641. doi: 10.1186/s12885-025-14041-y.
2
Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities.肺癌中PI3K信号通路的靶向治疗:进展、挑战与治疗机遇
J Transl Med. 2025 Feb 14;23(1):184. doi: 10.1186/s12967-025-06144-8.
3
Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene.

本文引用的文献

1
Prognostic implications of cellular senescence in resected non-small cell lung cancer.细胞衰老对切除的非小细胞肺癌的预后影响
Transl Lung Cancer Res. 2022 Aug;11(8):1526-1539. doi: 10.21037/tlcr-22-192.
2
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).吡咯替尼联合阿帕替尼治疗 HER2 突变转移性非小细胞肺癌的前瞻性、开放标签、单臂 2 期研究(PATHER2)。
BMC Med. 2022 Aug 29;20(1):277. doi: 10.1186/s12916-022-02470-6.
3
Tumor-promoting inflammation in lung cancer: A literature review.
敲低IGF2BP2可通过下调Spon2基因克服肺癌中的顺铂耐药性。
Hereditas. 2024 Dec 28;161(1):55. doi: 10.1186/s41065-024-00360-w.
4
Analysis and identification of mRNAsi‑related expression signatures via RNA sequencing in lung cancer.通过RNA测序分析和鉴定肺癌中与mRNAsi相关的表达特征
Oncol Lett. 2024 Sep 13;28(5):549. doi: 10.3892/ol.2024.14682. eCollection 2024 Nov.
5
Mathematical Modeling Support for Lung Cancer Therapy-A Short Review.肺癌治疗的数学建模支持——简要综述。
Int J Mol Sci. 2023 Sep 25;24(19):14516. doi: 10.3390/ijms241914516.
肺癌中的促肿瘤炎症:文献综述
Ann Med Surg (Lond). 2022 Jun 19;79:104022. doi: 10.1016/j.amsu.2022.104022. eCollection 2022 Jul.
4
Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach.运用系统生物学方法解析 miR-520c-3p 作为非小细胞肺癌免疫代谢的潜在靶点。
Oncotarget. 2022 May 24;13:725-746. doi: 10.18632/oncotarget.28233. eCollection 2022.
5
Recent Advances of Autophagy in Non-Small Cell Lung Cancer: From Basic Mechanisms to Clinical Application.自噬在非小细胞肺癌中的最新进展:从基本机制到临床应用
Front Oncol. 2022 May 4;12:861959. doi: 10.3389/fonc.2022.861959. eCollection 2022.
6
Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis.唾液酸结合免疫球蛋白样凝集素15促进非小细胞肺癌的进展,并与脊柱转移相关。
Ann Transl Med. 2022 Mar;10(6):281. doi: 10.21037/atm-22-764.
7
MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating by targeting .微小RNA-20a通过靶向上调促进非小细胞肺癌增殖。
Oncol Lett. 2022 May;23(5):148. doi: 10.3892/ol.2022.13269. Epub 2022 Mar 15.
8
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.AXL抑制剂在肺癌治疗中的发展:最新进展与挑战
Front Oncol. 2022 Mar 3;12:811247. doi: 10.3389/fonc.2022.811247. eCollection 2022.
9
The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles.肺癌中的PI3K/Akt/mTOR信号通路;致癌改变、治疗机遇、挑战以及纳米颗粒应用概述
Transl Oncol. 2022 Apr;18:101364. doi: 10.1016/j.tranon.2022.101364. Epub 2022 Feb 12.
10
Hallmarks of Cancer: New Dimensions.癌症的特征:新视角。
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.